알레르기 결막염의 진단 및 약물치료.
Background: Allergic conjunctivitis is an immune disease primarily attributed to a type 1 hypersensitivity reaction in the conjunctiva of the eye. Based on clinical findings and pathogenesis, allergic conjunctivitis is classified into the following subtypes: seasonal allergic conjunctivitis, perenni...
| Publicado en: | Journal of the Korean Medical Association / Taehan Uisa Hyophoe Chi Vol. 66; no. 9; pp. 556 - 564 |
|---|---|
| Autor principal: | |
| Formato: | tables/charts Journal Article |
| Publicado: |
Korean Medical Association
Sep2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=172759989&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 172759989 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 19758456 B9M7 jtl: Journal of the Korean Medical Association / Taehan Uisa Hyophoe Chi issn: 19758456 maglogo: N pubinfo: dt: Sep2023 vid: 66 iid: 9 pid: 64891 pub: Korean Medical Association place: , <Blank> artinfo: ui: 172759989 172759989 172759989 10.5124/jkma.2023.66.9.556 172759989 ppf: 556 ppct: 8 formats: fmt: @attributes: type: P tig: atl: 알레르기 결막염의 진단 및 약물치료. aug: au: 강 민 호 affil: 한양대학교 의과대학 한양대학교구리병원 안과 sug: subj: Conjunctivitis, Allergic Diagnosis Conjunctivitis, Allergic Drug Therapy Conjunctivitis, Allergic Classification Histamine Antagonists Administration and Dosage Administration, Oral Histamine Antagonists Adverse Effects Ophthalmic Solutions Administration and Dosage Steroids Administration and Dosage Keratoconjunctivitis Cyclosporine Administration and Dosage Tacrolimus Administration and Dosage Administration, Topical Rhinitis, Allergic, Perennial Drug Therapy ab: Background: Allergic conjunctivitis is an immune disease primarily attributed to a type 1 hypersensitivity reaction in the conjunctiva of the eye. Based on clinical findings and pathogenesis, allergic conjunctivitis is classified into the following subtypes: seasonal allergic conjunctivitis, perennial allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis. Current Concepts: The recommended initial treatment for allergic conjunctivitis involves the use of dual-effect agents exerting both antihistamine and mast cell stabilizing effects. If symptoms persist despite the application of these agents, coexisting allergic rhinitis should be considered a possible contributing factor, as this condition can also lead to ocular symptoms. Concurrent treatment of allergic rhinitis is necessary. Although oral antihistamines effectively alleviate symptoms associated with allergic conjunctivitis, potential systemic side effects must be carefully considered, particularly in older individuals and children. Steroid eye drops should be used for limited durations to minimize side effects. Unlike seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis involve both type 1 hypersensitivity reactions and type 4 hypersensitivity mediated by T cells. In cases where dual-effect agents or steroid eye drops fail to yield improvements, topical immunosuppressants such as cyclosporine A or tacrolimus can be effective. Discussion and Conclusion: The pharmacological treatment of allergic conjunctivitis involves the initial use of dual-effect agents, with concurrent treatment of allergic rhinitis if present. Importantly, atopic and vernal keratoconjunctivitis can potentially lead to permanent vision loss, necessitating the application of steroid eye drops or immunosuppressant eye drops. pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article language: Korean refInfo: holdings: @attributes: islocal: N |
|---|